Oxygenated machine perfusion mitigates surface antigen expression and improves preservation of predamaged donor livers.
The aim of the present study was to evaluate the potential benefit of machine preservation with the Belzer MPS or HTK solution, compared to standard cold storage, after procurement of marginal livers from non-heart beating donors in an experimental pilot study. Livers from male Wistar rats (250-300 g bw) were harvested after 60 min of cardiac arrest, flushed via the portal vein and cold stored submerged in HTK for 24 h at 4 degrees C while other organs were subjected to oxygenated machine perfusion with HTK or Belzer's MPS at 5 ml/min at 4 degrees C. Cold perfusion of livers with the non-colloidal HTK was not compromised by the lack of oncotic agents and there was no rise in vascular resistance during the 24 h of machine preservation with HTK or the colloidal Belzer MPS. Viability of the livers was assessed after the cold preservation period by warm reperfusion in vitro. Oxygenated machine perfusion was found to significantly increase viability of the livers vs simple cold storage with respect to portal vascular resistance upon reperfusion, enzyme release as well as functional recovery of oxygen utilization or bile production. Moreover, tissue antigen expression of ICAM-1 or histocompatibility antigen class II could be markedly reduced by oxygenated perfusion preservation as compared to cold storage. It is concluded that predamaged organs should preferably be preserved by oxygenated machine perfusion thus minimizing functional alterations and immunogenicity of the graft. In this setup HTK appeared equally effective as Belzer's MPS for machine preservation.
Lauschke
Holger
H
Surgical Research Division, University Clinic of Surgery, Sigmund Freud Str 25, 53127, Bonn, FRG.
Olschewski
Peter
P
Tolba
Rene
R
Schulz
Susi
S
Minor
Thomas
T
D000241:Adenosine / Q000008:administration & dosage / Q000494:pharmacology*; D000493:Allopurinol / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000954:Antigens, Surface / Q000032:analysis*; D015925:Cryopreservation; D005947:Glucose / Q000008:administration & dosage / Q000494:pharmacology*; D005978:Glutathione / Q000008:administration & dosage / Q000494:pharmacology*; D000949:Histocompatibility Antigens Class II / Q000032:analysis*; D007328:Insulin / Q000008:administration & dosage / Q000494:pharmacology*; D018799:Intercellular Adhesion Molecule-1 / Q000032:analysis*; D008099:Liver / Q000098:blood supply / Q000187:drug effects* / Q000201:enzymology / Q000276:immunology; D016031:Liver Transplantation; D008297:Male; D008353:Mannitol / Q000008:administration & dosage / Q000494:pharmacology*; D009926:Organ Preservation / Q000379:methods*; D019188:Organ Preservation Solutions / Q000008:administration & dosage / Q000494:pharmacology*; D010100:Oxygen / Q000494:pharmacology*; D010477:Perfusion / Q000295:instrumentation*; D010865:Pilot Projects; D011189:Potassium Chloride / Q000008:administration & dosage / Q000494:pharmacology*; D011343:Procaine / Q000008:administration & dosage / Q000494:pharmacology*; D011887:Raffinose / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012996:Solutions / Q000494:pharmacology; D020858:Tissue and Organ Harvesting / Q000379:methods*; D014655:Vascular Resistance / Q000187:drug effects
D000954:Antigens, Surface; C039984:Bretschneider cardioplegic solution; D000949:Histocompatibility Antigens Class II; D007328:Insulin; D019188:Organ Preservation Solutions; D012996:Solutions; C055206:University of Wisconsin-lactobionate solution; D018799:Intercellular Adhesion Molecule-1; D008353:Mannitol; D011343:Procaine; D000493:Allopurinol; D011189:Potassium Chloride; D005978:Glutathione; D005947:Glucose; D000241:Adenosine; D011887:Raffinose; D010100:Oxygen